| 1 |
34494293 | Withdrawn: SGLT2 inhibitor ipragliflozin poses a low risk of hypoglycaemia owing to its blood glucose-dependent urinary glucose excretion mechanism in mice. | 2022 Jun |
2 |
| 2 |
35192632 | Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. | 2022 |
2 |
| 3 |
33611885 | Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. | 2021 Nov |
3 |
| 4 |
34298949 | Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice. | 2021 Jul 8 |
2 |
| 5 |
34487707 | SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice. | 2021 Nov 5 |
3 |
| 6 |
31955626 | Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. | 2020 Feb - May |
5 |
| 7 |
32821334 | Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. | 2020 Jul 27 |
1 |
| 8 |
33015603 | Low dose of sodium-glucose transporter 2 inhibitor ipragliflozin attenuated renal dysfunction and interstitial fibrosis in adenine-induced chronic kidney disease in mice without diabetes. | 2020 Sep |
1 |
| 9 |
30914436 | Inhibition of Sodium Glucose Cotransporter 2 Attenuates the Dysregulation of Kelch-Like 3 and NaCl Cotransporter in Obese Diabetic Mice. | 2019 May |
2 |
| 10 |
31234839 | Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice. | 2019 Jun 24 |
1 |
| 11 |
31782258 | SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. | 2019 Nov |
2 |
| 12 |
31888083 | Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. | 2019 Dec 26 |
1 |
| 13 |
29154936 | Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution. | 2018 Jan 5 |
3 |
| 14 |
29352520 | Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. | 2018 Sep |
1 |
| 15 |
29374293 | Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. | 2018 Apr |
2 |
| 16 |
29425766 | Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents. | 2018 Mar 15 |
2 |
| 17 |
29507299 | Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. | 2018 Mar 5 |
1 |
| 18 |
29702076 | Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. | 2018 Jul 5 |
2 |
| 19 |
30021338 | Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats. | 2018 Sep |
1 |
| 20 |
28506912 | Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice. | 2017 Aug 15 |
1 |
| 21 |
26450351 | Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. | 2016 Feb |
2 |
| 22 |
26731267 | The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. | 2016 |
1 |
| 23 |
26977813 | Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. | 2016 |
1 |
| 24 |
27327650 | Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice. | 2016 |
1 |
| 25 |
27833913 | Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. | 2016 |
3 |
| 26 |
26366172 | Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice. | 2015 |
1 |
| 27 |
23707905 | Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. | 2013 Sep 5 |
3 |
| 28 |
22139434 | Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. | 2012 Apr |
5 |
| 29 |
22507206 | Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. | 2012 May 15 |
2 |
| 30 |
22971845 | Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. | 2012 |
3 |